Search
Zenas Biopharma Inc
ZBIOAdd to Watchlist
29.630USD
0.0000.00%
Close 09-23 16:00（ET）
1.87BMarket Cap
LossP/E TTM
Zenas Biopharma Inc (ZBIO) Stock Price Target & Forecast
Analyst Rating
Based on 8 analysts giving stock ratings to Zenas Biopharma Inc in the past month.
Strong Buy
5 Strong Buy
2 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
47.000USD+42.21%
ZBIO Analyst Recommendation Trends
In the current month, ZBIO has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ZBIO average Analyst price target in the last month is 47.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
5
5
5
5
5
5
5
5
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
8
8
8
8
8
8
8
ZBIO Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, ZBIO EPS is projected to reach -1.244 in FY2026Q3, following reported EPS of -1.766 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.03
-1.59
-1.12
-1.24
-1.27
Actual
-4.53
-1.46
-1.77
--
--
Surprise
-340.55%
+8.20%
-57.05%
--
--
FAQs
What is Zenas Biopharma Inc's price target?
Analysts forecast that Zenas Biopharma Inc's price target is USD 47.00, with the highest forecast at USD 59.00 and the lowest forecast at USD 32.00.
How have Zenas Biopharma IncZBIO's recent earnings per share performed?
The market expectation was USD -1.77, while Zenas Biopharma IncZBIO's earnings per share (EPS) for the previous quarter was USD -1.46. EPS for the next quarter is expected at USD -1.24.
What is the analyst rating for Zenas Biopharma Inc?
Based on the ratings of Zenas Biopharma Inc's stock from 8 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.